HER-2/neu amplification predicts poor survival in node-positive breast cancer
(1990) In Cancer Research 50(14). p.7-4332- Abstract
HER-2/neu protooncogene amplification and protein expression were analyzed with slot blot and Western blot techniques, respectively, in more than 300 invasive primary breast tumors of all stages. Amplification (2- greater than 30 copies) was found in 17% of these tumors and high expression was seen in 19%. There was a striking coincidence between gene amplification and high expression. Tumors associated with many involved axillary lymph nodes or with Stage IV disease were more often HER-2/neu amplified or overexpressed. Furthermore, gene alteration was strongly correlated with the absence of steroid receptors and with larger tumor size. High expression without gene amplification was seen in a minor subset of tumors of less aggressive... (More)
HER-2/neu protooncogene amplification and protein expression were analyzed with slot blot and Western blot techniques, respectively, in more than 300 invasive primary breast tumors of all stages. Amplification (2- greater than 30 copies) was found in 17% of these tumors and high expression was seen in 19%. There was a striking coincidence between gene amplification and high expression. Tumors associated with many involved axillary lymph nodes or with Stage IV disease were more often HER-2/neu amplified or overexpressed. Furthermore, gene alteration was strongly correlated with the absence of steroid receptors and with larger tumor size. High expression without gene amplification was seen in a minor subset of tumors of less aggressive character. Neither amplification nor overexpression was correlated with disease outcome for patients with negative axillary lymph nodes. For node-positive patients, however, HER-2/neu amplification was a significant predictor of early relapse and death (median follow-up = 45 months), and a similar trend, although not significant, existed for high gene expression. Multivariate analyses indicated that HER-2/neu alterations were not independent predictors of patient outcome.
(Less)
- author
- Borg, A LU ; Tandon, A K ; Sigurdsson, H ; Clark, G M ; Fernö, M LU ; Fuqua, S A ; Killander, D LU and McGuire, W L
- organization
- publishing date
- 1990-07-15
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Amino Acid Sequence, Biomarkers, Tumor/analysis, Blotting, Western, Breast Neoplasms/analysis, Female, Gene Amplification, Gene Expression, Humans, Immune Sera, Lymphatic Metastasis, Menopause, Molecular Sequence Data, Peptides/chemical synthesis, Prognosis, Protein-Tyrosine Kinases/genetics, Proto-Oncogene Proteins/analysis, Proto-Oncogenes, Receptor, ErbB-2, Receptors, Estrogen/analysis, Receptors, Progesterone
- in
- Cancer Research
- volume
- 50
- issue
- 14
- pages
- 6 pages
- publisher
- American Association for Cancer Research Inc.
- external identifiers
-
- pmid:1973070
- scopus:0025360473
- ISSN
- 0008-5472
- language
- English
- LU publication?
- yes
- id
- 22fdba8e-21ea-4bd8-8906-4264fd4602b0
- date added to LUP
- 2019-05-22 09:23:25
- date last changed
- 2024-06-12 15:47:16
@article{22fdba8e-21ea-4bd8-8906-4264fd4602b0,
abstract = {{<p>HER-2/neu protooncogene amplification and protein expression were analyzed with slot blot and Western blot techniques, respectively, in more than 300 invasive primary breast tumors of all stages. Amplification (2- greater than 30 copies) was found in 17% of these tumors and high expression was seen in 19%. There was a striking coincidence between gene amplification and high expression. Tumors associated with many involved axillary lymph nodes or with Stage IV disease were more often HER-2/neu amplified or overexpressed. Furthermore, gene alteration was strongly correlated with the absence of steroid receptors and with larger tumor size. High expression without gene amplification was seen in a minor subset of tumors of less aggressive character. Neither amplification nor overexpression was correlated with disease outcome for patients with negative axillary lymph nodes. For node-positive patients, however, HER-2/neu amplification was a significant predictor of early relapse and death (median follow-up = 45 months), and a similar trend, although not significant, existed for high gene expression. Multivariate analyses indicated that HER-2/neu alterations were not independent predictors of patient outcome.</p>}},
author = {{Borg, A and Tandon, A K and Sigurdsson, H and Clark, G M and Fernö, M and Fuqua, S A and Killander, D and McGuire, W L}},
issn = {{0008-5472}},
keywords = {{Amino Acid Sequence; Biomarkers, Tumor/analysis; Blotting, Western; Breast Neoplasms/analysis; Female; Gene Amplification; Gene Expression; Humans; Immune Sera; Lymphatic Metastasis; Menopause; Molecular Sequence Data; Peptides/chemical synthesis; Prognosis; Protein-Tyrosine Kinases/genetics; Proto-Oncogene Proteins/analysis; Proto-Oncogenes; Receptor, ErbB-2; Receptors, Estrogen/analysis; Receptors, Progesterone}},
language = {{eng}},
month = {{07}},
number = {{14}},
pages = {{7--4332}},
publisher = {{American Association for Cancer Research Inc.}},
series = {{Cancer Research}},
title = {{HER-2/neu amplification predicts poor survival in node-positive breast cancer}},
volume = {{50}},
year = {{1990}},
}